Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01540-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Yiyou Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Lundquist Institute, Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA. Hauptthemen laut MEDLINE: Amphotericin B, Mucormycosis, Antifungal Agents, Nanoparticles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Matinas BioPharma, HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID).
Abstract (Originalsprache)
Invasive mucormycosis (IM) is associated with high mortality and morbidity. MAT2203 is an orally administered lipid nanocrystal formulation of amphotericin B, which has been shown to be safe and effective against other fungal infections. We sought to compare the efficacy of MAT2203 to liposomal amphotericin B (LAMB) treatment in a neutropenic mouse model of IM due to Rhizopus arrhizus var. delemar or Mucor circinelloides f. jenssenii DI15-131. In R. arrhizus var. delemar -infected mice, 15 mg/kg of MAT2203 qd was as effective as 10 mg/kg of LAMB in prolonging median survival time vs placebo (13.5 and 16.5 days for MAT2203 and LAMB, respectively, vs 9 days for placebo) and enhancing overall survival vs placebo-treated mice (40% and 45% for MAT2203 and LAMB, respectively, vs 0% for placebo). A higher dose of 45 mg/kg of MAT2203 was not well tolerated by mice and showed no benefit over placebo. Similar results were obtained with mice infected with M. circinelloides . Furthermore, while both MAT2203 and LAMB treatment resulted in a significant reduction of ~1.0–2.0log and ~2.0–2.5log in Rhizopus delemar or M. circinelloides lung and brain burden vs placebo mice, respectively, LAMB significantly reduced tissue fungal burden in mice infected with R. delemar vs tissues of mice treated with MAT2203. These results support continued investigation and development of MAT2203 as a novel and oral formulation of amphotericin for the treatment of mucormycosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Lundquist Institute, Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
- Beni-Suef University, Beni Suef, Egypt.
- Matinas Biopharma, BedminsterBioPharma, Bedminster, New Jersey, USA.
- David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
ORCID-Profile: Theresa Matkovits, Jenel Cobb, Ashraf S Ibrahim
Förderung
- NIAID NIH HHS
- Matinas BioPharma
- HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID)
Zitieren
APA
Gu, Y., Gebremariam, T., Alkhazraji, S., Youssef, E., El-Gamal, S., Matkovits, T., Cobb, J., Mannino, R., & Ibrahim, A. S. (2024). Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01540-23
Vancouver
Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, et al. Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01540-23
BibTeX
@article{Gu2024,
author = {Gu, Yiyou and Gebremariam, Teclegiorgis and Alkhazraji, Sondus and Youssef, Eman and El-Gamal, Sabrina and Matkovits, Theresa and Cobb, Jenel and Mannino, Raphael and Ibrahim, Ashraf S},
title = {Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01540-23}
}
EUVIMED